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Editorial
The Signal Transduction Society (STS) [1] is delighted to
join BioMed Central with an open access journal. Over the
last years, our society members have increasingly appreci-
ated that access to scientific information generated by
publicly funded academic research must not be restricted
by commercial interests. With overwhelming support of
the society members, the presidial council and advisory
board of the STS are therefore now taking action and mov-
ing from an access-restricted print journal to online open
access publishing.
We are convinced that unduly limiting the flow of scien-
tific knowledge has a negative impact on the development
of benefits for mankind and believe that BioMed Central
is a highly valuable platform that is vital not only to scien-
tists but to society in general and hence deserves our
strong support.
The need for free information flow within the academic
community is especially true for rapidly evolving fields
such as cell signaling, which is now entering a new and
exciting era of development. The foundations in our
molecular understanding, laid by numerous colleagues
over the last decades, are now beginning to bear fruit in
the form of an increasing number of targeted, signal trans-
duction-modulating drugs entering clinical use. Over a
dozen examples can be found in current cancer therapies
alone, with more than a hundred further anti-cancer drug
candidates currently undergoing clinical evaluation. Nev-
ertheless, much still needs to be done to improve the out-
comes for countless severely suffering patients.
Cell Communication and Signaling (CCS) and the STS are
committed to playing an active part in the signal transduc-
tion research community by providing a stimulating and
collegial forum for the speedy publication of state-of-the
art research and discussions.
CCS intends to cover all aspects of cell signaling in health
and disease, from ultrastructural and molecular studies
with atomic resolution to signaling pathways, molecular
machines and signaling networks and further on to vari-
ous forms of inter-organismal signaling as, for example,
exerted by bacterial and viral pathogens. We will accept
timely reviews and commentaries as well as original arti-
cles with high-quality data in several formats (further
details below). Supported by the journal's editorial board
members and solicited expert reviewers, the editors will
make it a priority to ensure that publications are not
unduly delayed. It has become an aggravating fact of life
for many scientists that even well-prepared manuscripts
are rarely accepted without requests to perform multiple
additional experiments. Some manuscripts undergo four
or five rounds of resubmission, often resulting in publica-
tion delays for several years. This does not go down well
with many funding bodies and puts especially young
investigators at a disadvantage. The friendly reviewers'
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comment "This is a great paper well worth publishing as
soon as possible provided the authors can submit further
supporting data from a mouse knock-in and a genome-
wide gene expression array analysis of no less than 500
patient samples" has become a standing joke at many sci-
entific gatherings. In far too many cases, delaying manu-
scripts has less to do with improving manuscript quality
and more with conflicting interests of various kinds.
CCS will not be a part of this. We recognise that science is
a continuous process that is never finished and that real
proof comes primarily from independent confirmations
by other researchers. This is often not possible unless a
study, albeit incomplete, is publicly accessible.
If an original manuscript's data are novel, important and
technically sound, if the conclusions drawn are not
severely flawed, the quality of results and presentation are
state-of-the-art and the ethics acceptable, the work will be
published. The editors do, however, reserve the right to
add an editorial comment if they feel that this is impor-
tant for the scientific community. Authors may be invited
to comment on these. Reviewers will be requested to pro-
vide fair and constructive criticism that helps the authors
to improve their manuscripts.
We intend to publish the following types of contributions:
original research, reviews, commentaries, debate articles,
hypotheses, methodology articles and short reports. Fur-
ther details regarding these types of article is available via
the Cell Communication and Signaling about page [2].
As many readers will already know, it is not possible to
make high-quality open access publishing a reality with-
out a cost contribution of the authors. As such, Cell Com-
munication and Signaling levies an article-processing
charge (APC) for each accepted manuscript. There are cur-
rently over 300 institutions with BioMed Central mem-
bership [3] whereby the APC will be fully or partially
covered by the membership, and a number of funding
bodies allow their grants to be used to cover the APC [4].
Authors can request a waiver of the APC through the sub-
mission system and these will be considered where there
is a genuine inability to pay.
With the support of the STS, of our editorial board mem-
bers and of our valued colleagues around the globe, we
believe that CCS will achieve its goal, which is to become
an appreciated place to quickly disseminate exciting find-
ings from and to the signaling community and beyond.
We are looking forward to working with you all.
With warm regards,
Stephan M. Feller, Editor
Ralf Hass, President STS & Associate Editor
Ottmar Janssen, Presidial Council STS & Associate Editor
Karlheinz Friedrich, Presidial Council STS
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